260 related articles for article (PubMed ID: 18053665)
1. Differential inhibition of rat and human hepatic cytochrome P450 by Andrographis paniculata extract and andrographolide.
Pekthong D; Martin H; Abadie C; Bonet A; Heyd B; Mantion G; Richert L
J Ethnopharmacol; 2008 Feb; 115(3):432-40. PubMed ID: 18053665
[TBL] [Abstract][Full Text] [Related]
2. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6 beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro.
Murray M; Butler AM; Stupans I
J Pharmacol Exp Ther; 1994 Aug; 270(2):645-9. PubMed ID: 8071856
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes.
Yao HT; Chang YW; Lan SJ; Yeh TK
Food Chem Toxicol; 2008 Feb; 46(2):645-53. PubMed ID: 17950511
[TBL] [Abstract][Full Text] [Related]
4. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
Danie WA; Syrek M; Ryłko Z; Wójcikowski J
Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
[TBL] [Abstract][Full Text] [Related]
5. Effects of bioflavonoids on hepatic P450 activities.
Obermeier MT; White RE; Yang CS
Xenobiotica; 1995 Jun; 25(6):575-84. PubMed ID: 7483658
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
[TBL] [Abstract][Full Text] [Related]
7. Both cytochromes P450 2E1 and 3A are involved in the O-hydroxylation of p-nitrophenol, a catalytic activity known to be specific for P450 2E1.
Zerilli A; Ratanasavanh D; Lucas D; Goasduff T; Dréano Y; Menard C; Picart D; Berthou F
Chem Res Toxicol; 1997 Oct; 10(10):1205-12. PubMed ID: 9348445
[TBL] [Abstract][Full Text] [Related]
8. Antitumor drug ellipticine inhibits the activities of rat hepatic cytochromes P450.
Aimová D; Stiborová M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):437-40. PubMed ID: 16601806
[TBL] [Abstract][Full Text] [Related]
9. Influence of classic and atypical neuroleptics on caffeine oxidation in rat liver microsomes.
Daniel WA; Kot M; Wójcikowski J
Pol J Pharmacol; 2003; 55(6):1055-61. PubMed ID: 14730101
[TBL] [Abstract][Full Text] [Related]
10. Impact of Andrographis paniculata crude extract on mouse hepatic cytochrome P450 enzymes.
Jarukamjorn K; Don-in K; Makejaruskul C; Laha T; Daodee S; Pearaksa P; Sripanidkulchai BO
J Ethnopharmacol; 2006 May; 105(3):464-7. PubMed ID: 16406417
[TBL] [Abstract][Full Text] [Related]
11. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
12. Identification of a reversible component in the in vitro inhibition of rat hepatic cytochrome P450 2B1 by parathion.
Murray M; Butler AM
J Pharmacol Exp Ther; 1995 Feb; 272(2):639-44. PubMed ID: 7853177
[TBL] [Abstract][Full Text] [Related]
13. Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver.
Daniel WA; Syrek M; Ryłko Z; Kot M
Pol J Pharmacol; 2001; 53(6):615-21. PubMed ID: 11985335
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes.
Kim KA; Lee JS; Park HJ; Kim JW; Kim CJ; Shim IS; Kim NJ; Han SM; Lim S
Life Sci; 2004 Apr; 74(22):2769-79. PubMed ID: 15043991
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.
Kim KA; Park JY
Drug Metab Dispos; 2003 Sep; 31(9):1090-2. PubMed ID: 12920163
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate.
Kim JY; Baek M; Lee S; Kim SO; Dong MS; Kim BR; Kim DH
Drug Metab Dispos; 2001 Dec; 29(12):1555-60. PubMed ID: 11717174
[TBL] [Abstract][Full Text] [Related]
18. Effects of etodolac on P450 isoform-specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Zinno A; Nonaka K; Mukai H
Arzneimittelforschung; 2005; 55(12):744-8. PubMed ID: 16430028
[TBL] [Abstract][Full Text] [Related]
19. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components.
Chatterjee P; Franklin MR
Drug Metab Dispos; 2003 Nov; 31(11):1391-7. PubMed ID: 14570772
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
